The California Institute for Regenerative Medicine (CIRM) is seeking applications for its next round of Quest Awards (DISC2) for discovery stage research.

Applications are due August 2nd, 2022, at 2:00 PM PDT. Please visit the CIRM website for full details.  

The purpose of the Quest Awards is to promote the discovery of promising new stem cell-based or gene therapy technologies that could be translated to enable broad use and ultimately, improve patient care.

Applications should propose technology that is uniquely enabled by human stem/progenitor cells or directly reprogrammed cells, or that is uniquely enabling for the advancement of stem cell-based therapies or aimed at developing a genetic therapy approach.

The expected outcome, at the end of the award, is a candidate therapeutic or technology that can immediately progress to translational stage activities. For projects that culminate in a candidate that is a diagnostic, medical device or tool, the proposed project period must not exceed 2 years and direct project costs can be up to $500,000 per award. For projects that culminate in a candidate that is a therapeutic, an applicant may request up to $1,500,000 in direct project costs for up to 3 years duration.

Important Update: Please note that the DISC2 Program Announcement has been updated since the last round of applications. Please read the new program announcement on the CIRM funding website before submitting your application.

To receive updates about future funding opportunities through CIRM, please visit our e-mail newsletter page to sign up.